Quick Takeaways
- MORGAN STANLEY filed SCHEDULE 13G/A for Syndax Pharmaceuticals Inc Common Stock (SNDX).
- Disclosed ownership: 2.4%.
- Date of event: 31 Mar 2025.
MORGAN STANLEY - 31 Mar 2025 SCHEDULE 13G/A Report for Syndax Pharmaceuticals Inc Common Stock (SNDX)
- Filing Manager
- MORGAN STANLEY
- Reporting Manager
- Morgan Stanley
- Symbol
- SNDX
- Shares outstanding
- 85,000,542 shares
- Disclosed Ownership
- 2,040,013 shares
- Ownership
- 2.4%
- Form type
- SCHEDULE 13G/A
- Filing time
- 07 May 2025, 11:25:22 UTC
- Date of event
- 31 Mar 2025
- Previous filing
- 05 Feb 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"MORGAN STANLEY disclosed 2.4% ownership in Syndax Pharmaceuticals Inc Common Stock (SNDX) on 31 Mar 2025."
What Changed
- Previous schedule filing date: 05 Feb 2025.
- Current filing was accepted on 07 May 2025, 11:25.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | 2.4% | 2,040,013 | 0 | 1,994,022 | Chris O'Hara | Authorized Signatory, Morgan Stanley | |
| Morgan Stanley & Co. LLC | 0.2% | 213,174 | 0 | 213,174 | Chris O'Hara | Authorized Signatory, Morgan Stanley & Co. LLC |